ResMed appoints Christopher DelOrefice to board of directors, effective August 15, 2024

RESMED INC

DelOrefice is EVP and CFO of Becton Dickinson, brings 30+ years of audit, finance and strategic expertise.
Board expanded to 11 members; DelOrefice will serve on audit committee.
Appointment effective immediately; will stand for re-election at Nov 21, 2024 annual meeting.
DelOrefice previously served as VP Investor Relations at Johnson & Johnson and CFO of North America Hospital Medical Devices.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher DelOrefice

Director

RMD · RESMED INC

Effective: 2024-08-15
Filed: August 16, 2024, 7:59 PM ET

On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher DelOrefice was appointed as Director at RESMED INC.

Action: appointed
Role: Director

Exact text from the filing

On August 15, 2024, ResMed Inc. appointed Christopher DelOrefice to serve on its board of directors, with a term expiring at ResMed’s 2024 annual meeting of stockholders on November 21, 2024

View on SEC.gov

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-24-202204

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.